NCT05743621View on ClinicalTrials.gov

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2026

Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
DRUG

TVB-2640

TVB- 2640 at 100 mg, 150mg, 200 mg, 250 mg, or 300mg daily, orally; dose determined by BOIN dose escalation per the protocol

DRUG

Enzalutamide

160 mg daily PO

Trial Locations (1)

10021

RECRUITING

Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York

All Listed Sponsors
collaborator

Sagimet Biosciences Inc.

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER